{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:21:12Z","timestamp":1762899672635,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00345-019-02652-7","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T04:10:16Z","timestamp":1548907816000},"page":"2343-2353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4145-1081","authenticated-orcid":false,"given":"Amine","family":"Slaoui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Aoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Assenmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Al Hajj Obeid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Diamand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Regragui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Touzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mesfioui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Karmouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ameur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Elkhader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Koutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ibnattya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Roumeguere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"issue":"1","key":"2652_CR1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","volume":"4","author":"SP Kelly","year":"2018","unstructured":"Kelly SP, Anderson WF, Rosenberg PS, Cook MB (2018) Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 4(1):121\u2013127","journal-title":"Eur Urol Focus"},{"key":"2652_CR2","volume-title":"Cancer research UK prostate cancer mortality statistics","author":"A Angela Culhane","year":"2017","unstructured":"Angela Culhane A (2017) Cancer research UK prostate cancer mortality statistics. Cancer Research UK, London"},{"key":"2652_CR3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","volume":"36","author":"J Corfield","year":"2018","unstructured":"Corfield J, Perera M, Bolton D et al (2018) 68\u00a0Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 36:519","journal-title":"World J Urol"},{"key":"2652_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrurol.2016.175","volume":"14","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14:15\u201325","journal-title":"Nat Rev Urol"},{"issue":"Suppl 8","key":"2652_CR5","first-page":"mdy424.033","volume":"29","author":"AP Hoyle","year":"2018","unstructured":"Hoyle AP, Ali SA, James ND et al (2018) Effects of abiraterone acetate plus prednisone\/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. Ann Oncol 29(Suppl 8):mdy424.033","journal-title":"Ann Oncol"},{"key":"2652_CR6","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. \n                    https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"2652_CR7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8\u201310","journal-title":"J Clin Oncol"},{"issue":"11","key":"2652_CR8","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","volume":"6","author":"DK Reyes","year":"2015","unstructured":"Reyes DK, Pienta KJ (2015) The biology and treatment of oligometastatic cancer. Oncotarget 6(11):8491\u20138524","journal-title":"Oncotarget"},{"key":"2652_CR9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","volume":"73","author":"S Gillessen","year":"2018","unstructured":"Gillessen S, Attard G, Beer TM et al (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73:178\u2013211","journal-title":"Eur Urol"},{"issue":"4","key":"2652_CR10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvi\u00e8re O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618\u2013629","journal-title":"Eur Urol"},{"key":"2652_CR11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clgc.2015.09.011","volume":"14","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Mana-Ay M, Javadi MS, Szabo Z, Leal JP, Pomper MG, Pienta KJ, Ross AE, Gorin MA (2016) PSMA-based detection of prostate cancer bone lesions with F-DCFPyL PET\/CT: a sensitive alternative to Tc-MDP bone scan and NaF PET\/CT? Clin Genitourin Cancer 14:115\u2013118","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2652_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","volume":"43","author":"F Sterzing","year":"2016","unstructured":"Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, Afshar-Oromieh A, Debus J, Haberkorn U, Giesel FL (2016) (68)Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 43(1):34\u201341","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2652_CR13","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive 68\u00a0Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926\u2013937","journal-title":"Eur Urol"},{"issue":"2","key":"2652_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bju.13739","volume":"120","author":"S Albisinni","year":"2017","unstructured":"Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, Van Velthoven R (2017) Clinical impact of 68\u00a0Ga-prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int. 120(2):197\u2013203","journal-title":"BJU Int."},{"issue":"1","key":"2652_CR15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM (2018) The Impact of 68\u00a0Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 59(1):82\u201388","journal-title":"J Nucl Med"},{"issue":"1","key":"2652_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2017.02.036","volume":"72","author":"DG Murphy","year":"2017","unstructured":"Murphy DG, Sweeney CJ, Tombal B (2017) \u201cGotta catch \u2018em all\u201d, or do we? Pokemet approach to metastatic prostate cancer. Eur Urol 72(1):1\u20133","journal-title":"Eur Urol"},{"issue":"305","key":"2652_CR17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH (1953) Whole body irradiation; radiobiology or medicine? Br J Radiol 26(305):234\u2013241","journal-title":"Br J Radiol"},{"issue":"5","key":"2652_CR18","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/S0022-5347(05)64285-1","volume":"168","author":"IJ Powell","year":"2002","unstructured":"Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR et al (2002) Neoadjuvant therapy before radical prostatectomy for clinical T3\/T4 carcinoma of the prostate: 5-year followup, phase II Southwest Oncology Group Study 9109. J Urol 168(5):2016\u20132019","journal-title":"J Urol"},{"issue":"2","key":"2652_CR19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.juro.2008.04.012","volume":"180","author":"KN Chi","year":"2008","unstructured":"Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME (2008) Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 180(2):565\u2013570 (discussion 570)","journal-title":"J Urol"},{"issue":"33","key":"2652_CR20","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","volume":"32","author":"M-E Taplin","year":"2014","unstructured":"Taplin M-E, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL et al (2014) Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 32(33):3705\u20133715","journal-title":"J Clin Oncol"},{"issue":"19","key":"2652_CR21","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.27416","volume":"118","author":"RW Ross","year":"2012","unstructured":"Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W et al (2012) Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer 118(19):4777\u20134784","journal-title":"Cancer"},{"issue":"4","key":"2652_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canrad.2017.02.002","volume":"21","author":"JP Nesseler","year":"2017","unstructured":"Nesseler JP, Peiffert D, Vogin G, Nickers P (2017) Cancer, radiotherapy and immune system. Cancer Radiother 21(4):307\u2013315","journal-title":"Cancer Radiother"},{"issue":"4","key":"2652_CR23","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.juro.2007.11.063","volume":"179","author":"MJ Zelefsky","year":"2008","unstructured":"Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC (2011) Persistent, biologically meaningful prostate cancer after 1\u00a0year of androgen ablation and docetaxel treatment. J Clin Oncol 29(18):2574\u20132581","journal-title":"J Urol"},{"issue":"18","key":"2652_CR24","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2010.33.2999","volume":"29","author":"V Tzelepi","year":"2011","unstructured":"Zelefsky MJ, Reuter VE, Fuks Z, Scardino P (2008) Shippy A Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179(4):1368\u20131373\u00a0 \u00a0","journal-title":"J Clin Oncol"},{"issue":"6","key":"2652_CR25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrclinonc.2011.64","volume":"8","author":"E Comen","year":"2011","unstructured":"Comen E, Norton L, Massagu\u00e9 J (2011) Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 8(6):369\u2013377","journal-title":"Nat Rev Clin Oncol"},{"key":"2652_CR26","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1158\/1078-0432.CCR-13-2158","volume":"19","author":"KJ Pienta","year":"2013","unstructured":"Pienta KJ, Robertson BA, Coffey DS, Taichman RS (2013) The cancer diaspora: metastasis beyond the seed and soil hypothesis. Clin Cancer Res 19:5849\u20135855","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2652_CR27","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","volume":"123","author":"MC Haffner","year":"2013","unstructured":"Haffner MC, Mosbruger T, Esopi DM et al (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Investig 123(11):4918\u20134922","journal-title":"J Clin Investig"},{"issue":"6","key":"2652_CR28","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.urology.2012.09.001","volume":"80","author":"LR Folkersma","year":"2012","unstructured":"Folkersma LR, Manso LSJ, Romo IG, Sierra JM, G\u00f3mez CO (2012) Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 80(6):1328\u20131332","journal-title":"Urology"},{"issue":"8","key":"2652_CR29","first-page":"1996","volume":"49","author":"B Fisher","year":"1989","unstructured":"Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E (1989) Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Can Res 49(8):1996\u20132001","journal-title":"Can Res"},{"issue":"7\u20138","key":"2652_CR30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-0463.2008.01213.x","volume":"116","author":"GN Naumov","year":"2008","unstructured":"Naumov GN, Folkman J, Straume O, Akslen LA (2008) Tumor-vascular interactions and tumor dormancy. APMIS. 116(7\u20138):569\u2013585","journal-title":"APMIS."},{"key":"2652_CR31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2014.04.009","volume":"66","author":"C Gratzke","year":"2014","unstructured":"Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 66:602\u2013603","journal-title":"Eur Urol"},{"key":"2652_CR32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.canep.2014.04.002","volume":"38","author":"S Antwi","year":"2014","unstructured":"Antwi S, Everson TM (2014) Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 38:435\u2013441","journal-title":"Cancer Epidemiol"},{"key":"2652_CR33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 65:1058\u20131066","journal-title":"Eur Urol."},{"key":"2652_CR34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2009.12.034","volume":"57","author":"J Engel","year":"2010","unstructured":"Engel J, Bastian PJ, Baur H et al (2010) Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57:754\u2013761","journal-title":"Eur Urol"},{"key":"2652_CR35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","volume":"193","author":"A Heidenreich","year":"2015","unstructured":"Heidenreich A, Pfister D, Porres D (2015) Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 193:832\u2013838","journal-title":"J Urol"},{"key":"2652_CR36","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.eururo.2015.05.023","volume":"69","author":"P Sooriakumaran","year":"2016","unstructured":"Sooriakumaran P, Karnes J, Stief C et al (2016) A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 69:788\u2013794","journal-title":"Eur Urol"},{"key":"2652_CR37","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","volume":"34","author":"CG Rusthoven","year":"2016","unstructured":"Rusthoven CG, Jones BL, Flaig TW et al (2016) Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 34:2835\u20132842","journal-title":"J Clin Oncol"},{"key":"2652_CR38","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.euf.2017.06.016","volume":"3","author":"T Steuber","year":"2017","unstructured":"Steuber T, Berg KD, R\u00f8der MA et al (2017) Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? results from a prospective case-control study. Eur Urol Focus. 3:646\u2013649","journal-title":"Eur Urol Focus."},{"issue":"6","key":"2652_CR39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2018.07.006","volume":"74","author":"F Preisser","year":"2018","unstructured":"Preisser F, Mazzone E, Nazzani S, Bandini M, Tian Z, Marchioni M, Steuber T, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI (2018) Comparison of perioperative outcomes between cytoreductive radical prostatectomy and radical prostatectomy for nonmetastatic prostate cancer. Eur Urol 74(6):693\u2013696","journal-title":"Eur Urol"},{"key":"2652_CR40","doi-asserted-by":"publisher","first-page":"E250","DOI":"10.1111\/bju.12169","volume":"112","author":"AC Won","year":"2013","unstructured":"Won AC, Gurney H, Marx G, De Souza P, Patel MI (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 112:E250\u2013E255. \n                    https:\/\/doi.org\/10.1111\/bju.12169","journal-title":"BJU Int."},{"key":"2652_CR41","doi-asserted-by":"publisher","DOI":"10.23736\/S0393-2249.18.03319-2","author":"S Albisinni","year":"2018","unstructured":"Albisinni S, Aoun F, Diamand R, Al-Hajj Obeid W, Porpiglia F, Roumeguere T, De Nunzio C (2018) Cytoreductive prostatectomy: what is the evidence? A systematic review. Minerva Urol Nefrol. \n                    https:\/\/doi.org\/10.23736\/S0393-2249.18.03319-2","journal-title":"Minerva Urol Nefrol"},{"issue":"1","key":"2652_CR42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2016.04.031","volume":"72","author":"B L\u00f6ppenberg","year":"2017","unstructured":"L\u00f6ppenberg B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP, Sun M, Noldus J, Peabody JO, Trinh QD, Menon M, Abdollah F (2017) The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol 72(1):14\u201319","journal-title":"Eur Urol"},{"key":"2652_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008","author":"LMS Boev\u00e9","year":"2018","unstructured":"Boev\u00e9 LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, van Andel G (2018) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2018.09.008","journal-title":"Eur Urol"},{"issue":"10162","key":"2652_CR44","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O\u2019Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR, Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353\u20132366","journal-title":"Lancet"},{"key":"2652_CR45","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","volume":"67","author":"P Ost","year":"2015","unstructured":"Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67:852\u2013863","journal-title":"Eur Urol"},{"issue":"6","key":"2652_CR46","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/MOU.0000000000000441","volume":"27","author":"E Bleser De","year":"2017","unstructured":"De Bleser E, Tran PT, Ost P (2017) Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol. 27(6):587\u2013595","journal-title":"Curr Opin Urol."},{"issue":"5","key":"2652_CR47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446\u2013453","journal-title":"J Clin Oncol"},{"issue":"1","key":"2652_CR48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12885-017-3455-6","volume":"17","author":"N Radwan","year":"2017","unstructured":"Radwan N, Pillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT (2017) A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate CancEr (ORIOLE). BMC Cancer 17(1):453. \n                    https:\/\/doi.org\/10.1186\/s12885-017-3455-6","journal-title":"BMC Cancer"},{"issue":"3","key":"2652_CR49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2016.08.051","volume":"72","author":"F Montorsi","year":"2017","unstructured":"Montorsi F, Gandaglia G, Fossati N, Suardi N, Pultrone C, De Groote R, Dovey Z, Umari P, Gallina A, Briganti A, Mottrie A (2017) Robot-assisted salvage lymph node dissection for clinically recurrent prostate cancer. Eur Urol 72(3):432\u2013438","journal-title":"Eur Urol"},{"issue":"12","key":"2652_CR50","doi-asserted-by":"publisher","first-page":"djv261","DOI":"10.1093\/jnci\/djv261","volume":"107","author":"C Sweeney","year":"2015","unstructured":"Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, Li S, Philipson T, Buyse M, Halabi S, Kantoff P, Sartor AO, Soule H, Mahal B (2015) The development of intermediate clinical endpoints in cancer of the prostate (ICECaP). J Natl Cancer Inst 107(12):djv261. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv261","journal-title":"J Natl Cancer Inst"},{"key":"2652_CR51","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10585-014-9664-3","volume":"31","author":"A Uppal","year":"2014","unstructured":"Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR (2014) Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis 31:735\u2013748","journal-title":"Clin Exp Metastasis"},{"issue":"44","key":"2652_CR52","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1038\/onc.2013.451","volume":"33","author":"A Formosa","year":"2014","unstructured":"Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro\u2019 E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G, Candi E (2014) MicroRNAs, miR-154, miR- 299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR- 485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in meta- static prostate cancer cells. Oncogene 33(44):5173\u20135182","journal-title":"Oncogene"},{"issue":"12","key":"2652_CR53","doi-asserted-by":"publisher","first-page":"e28650","DOI":"10.1371\/journal.pone.0028650","volume":"6","author":"YA Lussier","year":"2011","unstructured":"Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR (2011) MicroRNA expression characterizes oligometastasis(es). PLoS One 6(12):e28650. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0028650","journal-title":"PLoS One"},{"issue":"12","key":"2652_CR54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.eursup.2017.09.005","volume":"16","author":"A Conti","year":"2017","unstructured":"Conti A, D\u2019Elia C, Cheng M, Santoni M, Piva F, Brunelli M, Lopez-Beltran A, Giulietti M, Scarpelli MM, Pycha A, Benedetto Galosi A, Artibani W, Cheng L, Montironi R, Battelli N, Lusuardi L (2017) Oligometastases in genitourinary tumors: recent insights and future molecular diagnostic approach. Eur Urol Suppl. 16(12):309\u2013315","journal-title":"Eur Urol Suppl."},{"issue":"1","key":"2652_CR55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3892\/ijo.2015.3011","volume":"47","author":"K Kawakami","year":"2015","unstructured":"Kawakami K, Fujita Y, Kato T, Mizutani K, Kameyama K, Tsumoto H, Miura Y, Deguchi T, Ito M (2015) Integrin \u03b24 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance. Int J Oncol 47(1):384\u2013390","journal-title":"Int J Oncol"},{"issue":"16","key":"2652_CR56","doi-asserted-by":"crossref","first-page":"14318","DOI":"10.18632\/oncotarget.3960","volume":"6","author":"M Trerotola","year":"2015","unstructured":"Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR (2015) Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget 6(16):14318\u201314328 (Erratum in: Oncotarget. 2015;6(32):34038)","journal-title":"Oncotarget"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02652-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02652-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02652-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T19:08:31Z","timestamp":1580411311000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02652-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2652"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02652-7","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"type":"print","value":"0724-4983"},{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"21 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}